13 recruiting, 13 unknown, 3 completed, 1 active not recruiting. 19 Phase 2, 17 Phase 1, 5 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow Toripalimab Injection: new trials by email Literature Review of Toripalimab Injection trials Research Report on Toripalimab Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors IPG7236, Toripalimab Injection - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Nanjing Immunophage Biotech Co., Ltd | 52 | 2026-06-16 | 2026-06-29 |
| Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Chiauranib, Toripalimab Injection, Albumin-paclitaxel Injection - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Not yet recruiting | Chipscreen Biosciences, Ltd. | 558 | 2026-03-31 | 2026-03-03 |
| A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer LBL-024 for Injection, albumin-bound Paclitaxel injection, Toripalimab Injection - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 220 | 2026-01-27 | 2026-02-12 |
| A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma. LBL-024 for Injection, Toripalimab Injection - Advanced Melanoma | Phase 1 / Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2025-09-05 | 2026-10-21 |
| A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer SHR-A1811 for Injection, SHR-1316 Injection, Toripalimab Injection - PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 400 | 2025-08-20 | 2025-12-18 |
| 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer 9MW2821, Toripalimab Injection - Urothelial Carcinoma | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 90 | 2025-08-01 | 2026-01-02 |
| Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 FS-8002 injection, Toripalimab Injection, Chemotherapy - Advanced Solid Tumors | Phase 1 | Recruiting | Shanghai Pushi Medical Science Co. Ltd | 66 | 2025-02-24 | 2026-08-04 |
| 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer 9MW2821, Toripalimab, Gemcitabine - Urothelial Carcinoma | Phase 3 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 460 | 2024-08-22 | 2024-09-19 |
| A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) LVGN6051 Monoclonal Antibody Injection, toripalimab Injection, Paclitaxel injection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Lyvgen Biopharma Holdings Limited | 64 | 2024-06-21 | 2026-05-19 |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) S-1, Toripalimab, Intensity-modulated radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 140 | 2024-03-01 | 2024-03-12 |
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Risen (Suzhou) Pharma Tech Co., Ltd. | 306 | 2024-01-11 | 2025-07-25 |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab - Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 756 | 2023-11-15 | 2026-07-27 |
| 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer 9MW2821, Toripalimab - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 100 | 2023-09-27 | 2024-09-19 |
| A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors RC118, Toripalimab, RC148 - Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | RemeGen Co., Ltd. | 48 | 2023-08-03 | 2025-01-29 |
| IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors MSC-IFNα, Nab paclitaxel, Cyclophosphamide - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 40 | 2023-02-23 | 2023-04-28 |
| A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection - Locally Advanced or Metastatic Urothelial Carcinoma | Phase 3 | Withdrawn | Shanghai Junshi Bioscience Co., Ltd. | 2022-09-06 | 2026-07-09 | |
| Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer CT-707, Toripalimab, Gemcitabine - Advanced Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Shouyao Holdings (Beijing) Co. LTD | 114 | 2022-08-11 | 2023-11-22 |
| Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma TQB2618 injection, Toripalimab injection - Melanoma | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 50 | 2022-08-09 | 2023-07-07 |
| A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors JS004, Toripalimab Injection - Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer | Phase 1 | Terminated | Shanghai Junshi Bioscience Co., Ltd. | 31 | 2022-07-28 | 2025-12-03 |
| A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors LBL-007 Injection, Toripalimab Injection - Advanced Malignant Tumors | Phase 1 / Phase 2 | Completed | Nanjing Leads Biolabs Co.,Ltd | 80 | 2021-11-30 | 2025-06-03 |
Showing 20 of 33. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Transitional Cell (3) · Triple Negative Breast Neoplasms (3) · Esophageal Squamous Cell Carcinoma (2) · Melanoma (2) · Small Cell Lung Carcinoma (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Epstein-Barr Virus Infections (1) · Liver Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Thoracic Neoplasms (1)
Shanghai Junshi Bioscience Co., Ltd. (5) · Mabwell (Shanghai) Bioscience Co., Ltd. (3) · Nanjing Leads Biolabs Co.,Ltd (3) · Beijing Friendship Hospital (2) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2) · Abbisko Therapeutics Co, Ltd (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chinese PLA General Hospital (1) · Chipscreen Biosciences, Ltd. (1) · Fujian Cancer Hospital (1) · Hubei Cancer Hospital (1) · Lyvgen Biopharma Holdings Limited (1) · Nanjing Immunophage Biotech Co., Ltd (1) · RemeGen Co., Ltd. (1) · Risen (Suzhou) Pharma Tech Co., Ltd. (1)
China (33) · Georgia (1) · Netherlands (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1)
Zhao Wang (2) · Dong Wang, PH.D (1) · J L Zheng, Director (1) · Juan Li, MD (1) · Keli Zhong, PhD (1) · Mian Xi, MD (1) · Shanzhi Gu, MD (1) · Shukui Qin, PhD (1) · Tao Jiang, PH.D (1) · Tianshu Liu, ph.D (1) · Wan He, PhD (1) · WeiDong Han, PhD (1) · Ye Guo (1) · Ye Guo, Doctor (1) · Yinghui Sun, PhD (1)
PMID 34351356, PMID 35419831, PMID 36990609, PMID 37195667, PMID 40288679, PMID 42260304